Femasys appoints Wendy Perrow to board, replacing William Witte

FEMASYS INC

William Witte resigned from board effective Jan 19, 2022; no disagreement cited.
Wendy Perrow elected as Class II director, to serve on Compensation Committee.
Anne Morrisey added to Nominating and Governance Committee.
Perrow brings biotech leadership; previously CEO of AsclepiX and Alba Therapeutics.
Company advancing FemaSeed de novo trial and FemBloc pivotal trial in 2022.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Witte

Director

FEMY · FEMASYS INC

Effective: 2022-01-19
Successor: Wendy Perrow
Filed: January 20, 2022, 6:59 PM ET

Effective January 19, 2022, the Board of Directors of Femasys Inc. (the “Company”) accepted William Witte’s resignation from the Board of Directors.

Appointed

Wendy Perrow

Director

FEMY · FEMASYS INC

Effective: 2022-01-19
Filed: January 20, 2022, 6:59 PM ET

the Board of Directors elected Wendy Perrow as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Witte resigned as Director at FEMASYS INC.

Action: resigned
Role: Director

Exact text from the filing

Effective January 19, 2022, the Board of Directors of Femasys Inc. (the “Company”) accepted William Witte’s resignation from the Board of Directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy Perrow was elected as Director at FEMASYS INC.

Action: elected
Role: Director

Exact text from the filing

the Board of Directors elected Wendy Perrow as a director of the Company.

View on SEC.gov

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-22-002108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.